Newsroom

PCMA Blog
  • From Promise to Progress: The Rise of Biosimilars

    October 16, 2026
  • Competition Can’t Wait: Policymakers Must Address Patent Abuse

    October 14, 2026
  • The Real Test for DOL’s Proposed PBM Rule: Is It Helping or Hurting Affordability?

    October 9, 2026

with Amanda Frost

Missing from the VI Debate: Data That Shows It’s A Problem

By Amanda Frost, PhD Vice President, Research, PCMA Concerns about high health care costs are prevalent and appropriate, but can be often focused on the wrong place. Vertical integration (VI) is one area that is receiving attention from state and federal policymakers, with a focus on health insurers, pharmacy benefit managers (PBMs), and pharmacies. But the rhetoric around VI’s costs is increasingly disconnected from the data.  Evidence of

Read More »

Greg Lopes

Vice President,
Public Affairs

glopes@pcmanet.org
202-756-5713

Federal Regulatory Comment Letters

The Federal Regulatory Comment Letters section houses PCMA’s formal public responses to proposed federal regulations and rulemakings that affect pharmacy benefit managers (PBMs) and broader health care policy.